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Antiproliferation and Redifferentiation in Thyroid Cancer Cell 
Lines by Polyphenol Phytochemicals 
Thyroid carcinogenesis is accompanied by loss of thyroid-specific functions and refractory 
to radioiodine and thyroid stimulating hormone (TSH) suppression therapy. Redifferentiating 
agents have been shown to inhibit tumor growth and improve the response to conventional 
therapy. Polyphenol phytochemicals (PPs) in fruits and vegetables have been reported to 
inhibit cancer initiation, promotion, progression and induce redifferentiation in selected 
types. In this study we examined PPs induce redifferentiation in thyroid cancer cell lines. 
We investigated the effects of genistein, resveratrol, quercetin, kaempferol, and resorcinol 
on the F9 embryonal carcinoma cell differentiation model. The thyroid cancer cell lines, 
TPC-1, FTC-133, NPA, FRO, and ARO, displayed growth inhibition in response to genistein, 
resveratrol, quercetin. We further demonstrated that genistein decreased the dedifferention 
marker CD97 in NPA cells and resveratrol decreased CD97 in FTC-133, NPA, FRO cells and 
quercetin decreased CD97 in all cell lines. We observed increased expression of differentiation 
marker NIS in FTC-133 cells in response to genistein, and resveratrol but no change in NPA, 
FRO, ARO cells. Quercetin increased or induced NIS in FTC-133, NPA, FRO cells. These 
findings suggest that PPs may provide a useful therapeutic intervention in thyroid cancer 
redifferentiation therapy. 
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INTRODUCTION
Differentiated thyroid cancers (DTC) maintain thyroid specific 
functions even with regional metastasis, respond to surgical treat-
ment, radioiodine therapy and TSH suppression therapy. How-
ever, poorly differentiated (PDTC) or anaplastic thyroid cancers 
(ATC) do not respond to conventional therapy, leading to poor 
outcome (1). During the dedifferentiation process, the cancer 
loses thyroid-specific gene expression, including the ability to 
absorb radioiodine and to express the TSH receptor; as such ra-
dioiodine therapy or thyroid stimulating hormone (TSH) sup-
pressive therapy is not effective in PDTC/ATC. Dedifferentiated 
cancers display more rapid growth properties and are refractory 
to chemotherapy, external beam radiation therapy, and show 
poor outcomes in comparison with differentiated cancers.
  Redifferentiation therapy is defined as a treatment to inhibit 
tumor growth and regain thyroid-specific functions in PDTC 
and ATC as a mean of increasing the response to conventional 
therapy (2). The goals of such therapy are to regain the expres-
sion of differentiation markers, including the sodium iodine 
symporter (NIS), and to reduce levels of the dedifferentiation 
marker CD97. Plasma membrane expression of NIS in thyroid 
follicular cells is necessary to absorb iodine into the cell and, as 
such thyroid cancers with reduced NIS expression display im-
paired iodine uptake (3). CD97 is a dedifferentiation marker that 
is increased during cancer progression and metastasis, and is 
reduced by redifferentiating agent such as retinoid acid (RA) in 
partially dedifferentiated thyroid cancer cells (4). 
  Currently available redifferentiating agents include RA, his-
tone deacetylase inhibitors (HDAC inhibitors), and peroxisome 
proliferator activated receptor gamma (PPARγ) agonist. Their 
effectiveness in dedifferentiated cancers and patient tolerability 
have been variable (1, 2, 5-7). Thus, this is a reason why more 
effective and better tolerated agents are needed.
  The polyphenol phytochemicals (PPs) such as quercetin, res-
veratrol, genistein, and kaempferol (8-11), are present in fruits 
and vegetables, and inhibit cancer initiation, promotion and pro-
gression in vivo and in vitro. Moreover these compounds have 
been reported to induce redifferentiation in specific cancer types 
(12-14).
  The F9 mouse embryonal carcinoma cell model (F9 cells) is 
frequently used to evaluate cellular morphological and molec-
ular differentiation changes following drug and hormone treat-
ment. The time duration of the growth cycle is very short and no Kang HJ, et al.  •  Polyphenol Phytochemicals and Redifferentiation in Thyroid Cancer
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self differentiation is evident; however, drugs including RA have 
been demonstrated to induce differentiation after 72 hr of treat-
ment. The primitive endoderm-like structure is formed with the 
expression of laminin B1, collagen type IV, and tissue plasmino-
gen activator (tPA), followed by growth inhibition (15). 
  In the present study, we tried to demonstrate that some PPs 
have the ability to induce antiproliferation and redifferentiation 
in thyroid cancer cell lines using the F9 embryonal carcinoma 
cell differentiation model.
MATERIALS AND METHODS
Cell lines and culture
F9 embryonal cancer, cells were cultured in DMEM (Sigma, St 
Louis, MO, USA) with 20% fetal bovine serum (FBS). TPC-1 (pap-
illary thyroid cancer cell line) and FTC-133 (follicular thyroid 
cancer cell line), cells were cultured in DMEM with 10% FBS. 
NPA (poorly differentiated papillary thyroid cancer cell line), 
FRO (undifferentiated/anaplastic thyroid cancer cell line), and 
ARO (undifferentiated/anaplastic thyroid cancer cell line) cells 
were cultured in RPMI1640 (Sigma) with 10% FBS. 
Reagents
Polyphenol phytochemical (resveratrol, genistein, quercetin, 
kaempferol, resorcinol (Sigma, Fig. 1) were dissolved in dimeth-
ylsulfoxide (DMSO; Sigma) at appropriate concentrations prior 
to dilution in tissue-culture medium such that the final concen-
tration of DMSO not exceed 0.1% (v/v). Each reagent was as-
sessed for a concentrations-dependent effect in F9 and thyroid 
cancer cells. In F9 cells, 0.2 μM ATRA (all-trans-retinoic acid; 
Sigma) was used as a positive control.
Cell proliferation and growth inhibition
Cell proliferation and growth inhibition was measured by colo-
rimetric dimethyl-thiazol-diphenyltetrazolium bromide (MTT) 
proliferation assays. 
RT-PCR and semi quantitative analysis
At 72 hr after the administration of reagents, RT-PCR was per-
formed for laminin B1, collagen type IV, and tissue plasminogen 
activator (tPA) mRNA in F9 cell. To assess thyroid cancer redif-
ferentiation, RT-PCR was performed for NIS, CD97 mRNA; 36B4 
mRNA was assessed as a housekeeping gene. RNA extraction 
and complementary DNA preparation were performed by con-
ventional methods. The primers for each gene were designed and 
PCRs performed according to the following conditions (anneal-
ing temperature/cycles). 36B4: forward 5´-CAGCTCTGGAGA-
AACTGCTG-3´, reverse 5´-GTGTACTCAGTCTCCACAGA-3´ 
(49°C/25 cycles); laminin B1: forward 5´-TGAATTCTCACTG-
CAGACATGGTGAAG-3´, reverse 5´-ATGGATCCCTCACTTAT-
GTCCTTAAGGA-3´ (48°C/30 cycles); collagen type IV: forward 
5´-ATGAATTCTCAGCGTCTGGCTTCTGCT-3´, reverse: 5´-AT-
GGATCCGTTGCATCCTGGGATACCTG-3´ (62°C/30 cycles); tPA 
forward 5´-TTGGGCAGAACATACAGGGTGGTC-3´, reverse 5´- 
CTGGCATGCATCGTGGAGGTCTT-3´ (62°C/30 cycles); NIS for-
ward 5´-GCCCTCATCCTGAACCAAGTG-3´, reverse 5´-TGATC-
CGGGAGTGGTTCTG-3´ (50°C/30 cycles); CD97 forward 5´-TC-
CTGCCGGCAGCTCCAACC-3´, reverse 5´-GGCAGCGGCAG-
CTGTATGAAC-3´ (58°C/30 cycles). PCR was conducted for the 
indicated number of cycles with denaturation at 95°C for 60 sec, 
annealing at the temperatures indicated for 60 sec, and exten-
sion at 72°C for 20 sec. Each RT-PCR experiment from F9 cell 
and thyroid cancer cells was performed in triplicate. 
  In thyroid cancer cell experiments, the PCR results were ana-
lyzed by semi quantitative methods using the Total Lab TL100 
program (Nonlinear Dynamics Ltd., Newcastle, UK) compen-
sated by comparing the 36B4 density of each PCR.
Statistical analyses
Statistical analyses were performed using the SPSS software (ver. 
12.0 for Windows SPSS, Chicago, IL, USA). All MTT assays were 
performed in triplicate and mean value were compared using 
Student’s t-test and one-way ANOVA. A P value < 0.05 was con-
sidered to indicate statistical significance.
RESULTS
F9 cell proliferation assays
We initially assessed the effects of resorcinol, genistein, resvera-
trol, kaempferol and quercetin on F9 cell proliferation at con-
centrations of 1, 10, 50, and 100 μM respectively. Fig. 2 shows 
that resorcinol did not inhibit growth at concentrations below 
100 μM, while genistein, resveratrol, kaempferol and quercetin 
all inhibited cellular growth in a dose dependent manner. Fol-
Quercetin Kaempferol Resorcinol Genistein Resveratrol
Fig. 1. Structure of polyphenol phytochemicals and resorcinol.Kang HJ, et al.  •  Polyphenol Phytochemicals and Redifferentiation in Thyroid Cancer
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lowing the administration of each agent, MTT assays were per-
formed at 24, 48, 72, 96, and 120 hr. Fig. 3 demonstrates that F9 
cell growth was increased in a time-dependent manner in con-
trol cells (DMSO only), while quercetin, resveratrol and genis-
tein inhibited cell growth up to 120 hr (P < 0.05). Kaempferol did 
not affect F9 cell growth.
  We thus selected quercetin, resveratrol and genistein for fur-
ther experiments.
Quantification of F9 cell differentiation markers by RT-PCR
Genistein, resveratrol and quercetin at concentration of 10 μM 
and ATRA (positive control) at a concentration of 0.2 μM were 
administered to F9 cells in culture. After 72 hr, RT-PCR was per-
formed for laminin B1, tPA and collagen type IV mRNA. Fig. 4 
demonstrates that genistein, resveratrol and quercetin increased 
the levels of these differentiation markers compared with the 
DMSO-alone negative control.
Thyroid cancer cell proliferation assays
Fig. 5 demonstrates that when genistein and quercetin were ad-
ministered for 72 hr, the growth of TPC-1, NPA, FTC-133, FRO, 
and ARO cells was inhibited in a dose-dependent manner (P < 
0.05). Resveratrol inhibited the growth of these cells from 10 μM 
excluding TPC-1 cells that displayed increased levels of growth. 
TPC-1 proliferation was, however, inhibited at resveratrol con-
centrations of 50 μM or more.
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Fig. 2. F9 cell MTT assays in the presence of each 
polyphenol phytochemicals. Results are the mean ± 
SD of triplicate experiments. P values were determined 
by comparison with the control samples using Stu-
dent’s t- test. (A) F9 cell MTT assays in the presence 
of resorcinol, (B) F9 cell MTT assays in the presence 
of genistein, (C) F9 cell MTT assays in the presence 
of resveratrol, (D) F9 cell MTT assays in the presence 
of kaempferol, (E) F9 cell MTT assays in the presence 
of quercetin.
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Fig. 3. F9 cell MTT assays in the presence of each polyphenol (10 µM). Results are 
the mean ± SD of triplicate experiments. P values were determined by comparison 
with the control samples using Student’s t-test. *P = 0.001; 
†P < 0.001; 
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Fig. 4. F9 cell differentiation marker expression in the presence of ATRA and the poly-
phenol phytochemicals. Representative results are shown. 1, DMSO; 2, ATRA 0.2 µM; 
3, Genistein 10 µM; Resveratrol 10 µM; Quercetin 10 µM.
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Assessment the expression of thyroid cancer differentiation 
markers by RT-PCR
RT-PCR for CD97 and NIS mRNA was performed following 72 
hr of treatment for TPC-1 cells: genistein (100 μM), resveratrol 
(50 μM), quercetin (100 μM), for NPA cells: genistein (20 μM), 
resveratrol (50 μM), qeurcetin (100 μM), for FTC-133 cells: ge-
nistein (20 μM), resveratrol (20 μM), quercetin (20 μM), for FRO 
cells: genistein (50 μM), resveratrol (50 μM), quercetin (20 μM), 
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Fig. 5. MTT assays in thyroid cancer cell lines in response to polyphenol phytochemi-
cals. Results are shown as the mean ± SD of triplicate esperiments. *,†P values were 
determined in comparison with the control using Student’s t-test. a, b, c, d, e: P values 
were determined using one way ANOVA. (A) MTT assays in thyroid cancer cell lines in 
response to resveratrol. *,†P < 0.01: a, b, c, d, e; P < 0.001. (B) MTT assays in thy-
roid cancer cell lines in response to genistein; *P < 0.05, 
†P < 0.01: a, b, c ,d, e; P < 
0.001. (C) MTT assays in thyroid cancer cell lines in response to quercetin. * P > 0.05, 
†P < 0.05: a, b, c ,d, e; P < 0.001.
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Fig. 6. RT-PCR for CD97 mRNA in thyroid cancer cell lines. (A) RT-PCR for CD97 mRNA levels in thyroid cancer cell lines following genistein, resveratrol or quercetin treatment 
(1, Control; 2, Genistein 100 µM; 3, Resveratrol 50 µM; 4, Quercetin 100 µM; 5, Control; 6, Genistein 20 µM; 7, Resveratrol 50 µM; 8, Quercetin 100 µM; 9, Control; 10, Ge-
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19, Resveratrol 20 µM; 20, Quercetin 20 µM). (B) Relative CD97 density in thyroid cancer cell lines following genistein, resveratrol or quercetin treatment. Results are normal-
ized to the relative density of 36B4.
for ARO cells: genistein (50 μM), resveratrol (20 μM), quercetin 
(20 μM). In contrast to the other cell lines under investigation, 
TPC-1 cells did not express the dediffenetiation marker CD97. 
We observed a decrease in CD97 expression following genistein 
treatment in NPA cells. Resveratrol decreased CD97 in FTC-133, 
NPA and marginally decreased CD97 in FRO cells, while qurce-
tin decreased CD97 levels in FTC-133, NPA, FRO, and ARO cells. 
Expression of CD97 in TPC-1 cells was unaffected by the pres-Kang HJ, et al.  •  Polyphenol Phytochemicals and Redifferentiation in Thyroid Cancer
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A B
ence of any of the PPs (Fig. 6). NIS was expressed in TPC-1 and 
FTC-133 cells. While the levels of NIS were unchanged in the 
presence of genistein, resveratrol and quercetin in TPC-1 cells, 
all three compounds increased NIS levels in FTC-133 cells. Ge-
nistein and resveratrol both failed to induce in NPA, FRO or ARO 
cells. Qurcetin did not induce NIS in ARO cells but did induce 
NIS in dedifferentiated/anaplastic NPA and FRO cells (Fig. 7). 
DISCUSSION
RA, HDAC inhibitor, and PPARγ agonists are effective rediffer-
entiation therapies in partially dedifferentiated thyroid cancers, 
but are ineffective undifferentiated/anaplastic cancers and dis-
play high patient toxicity or effectiveness only in vitro. Polyphe-
nol phytochemicals have been reported to inhibit cancer initia-
tion, promotion and progression in vivo or in vitro and more-
over have been reported to induce redifferentiation in specific 
cancer types (12-14). We present the first report that identifies 
the ability of PPs to promote tumor growth inhibition in both 
partially dedifferentiated cancer and dedifferentiated/anaplas-
tic cancers.
  We demonstrated that genistein (rich in soybeans), resvera-
trol (rich in grapes), quercetin (rich in onions) inhibit the tumor 
growth of TPC-1, FTC-133, NPA, FRO, and ARO cell lines. The 
mechanism of the growth inhibition of genistein, resveratrol and 
quercetin is thought to involve the inhibition of epidermal growth 
factor (EGF), NF-κB, cyclin D and protein tyrosine kinase, all of 
which increase tumor promotion, progression, and inreases cas-
pase which can induce apoptosis (16-18). They have been test-
ed in normal and cancer cultured cells, and shown that these 
compounds induced apoptosis in cultured cancer cells but not 
in their normal counterparts up to 100 μM, so these effects were 
not by general toxicity (19). Other studies have suggested that 
PPs act as phytoestrogens and inhibit the estrogen-dependent 
growth of estrogen receptor (ER) - positive cancer cells (20) and 
specific cancer cells (NPA, FRO) that express ER (11). We ob-
served increased TPC-1 cell growth in response to low dose res-
veratrol (10 μM), most likely caused by its phytoestrogenic ef-
fects, stimulating the estrogen receptor α (ERα) and inhibitory 
estrogen receptor β (ERβ). The dose of resveratrol displays bipha-
sic effects in MCF-7 breast cancer cells and low dose are thought 
to affect growth stimulation (21). However, no report has de-
scribed the expression of ER in TPC-1 cells. 
  CD97 is a representative dedifferentiation marker in thyroid 
cancers that is stimulated by EGF, and can be inhibited genis-
tein, resveratrol and quercetin (16), consistent with their effects 
on cancer cell observed in our study.
  The dedifferentiation process is accompanied by both genet-
ic mutations and epigenetic changes. During dedifferentiation 
process, a loss of NIS gene expression occurs, caused by hyper-
methylation of the NIS gene; this is recovered by demethylating 
agent 5-azacytidine (22). Additionally, NIS expression is induc-
ed by TSH mediated by TSH receptor (TSHR). Dedifferentiated 
thyroid cancers are accompanied by a loss of the TSHR gene 
promoter hypermethylation and is restored by 5-azacytidine 
(23). DNA methylation is mediated by DNA methyltransferases 
(DNMT) and numerous cancers including thyroid cancers, have 
been reported to have stimulated hypermethylation (22, 23). In 
this study, genistein, resveratrol and quercetin all incresed NIS 
expression in FTC-133 cells while quercetin also incresed NIS 
expression in dedifferentiated/anaplastic NPA and FRO cells. 
Quercetin has been reported to reverse DNA hypermethylation 
in a dose-dependent manner in other cancers (24). Genistein 
has been reported to reverse retinoic acid receptor β (RARβ) pro-
moter hypermethylation and increase RARβ in prostate and 
esophageal cancers (25). There is no report regarding the effects 
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of resveratrol in relation to DNA methylation; however, most of 
PPs are substrates of catechol O-methyltransferase (COMT) and 
are converted to S-adenosyl-L-homocysteine (SAH) by COMT, 
an antagonist of DMNT (24). Additionally, resveratrol has been 
reported to increase the transcription of PPARγ, which can in-
duce thyroid cancer redifferentiation (26). RA acts through bind-
ing with RARβ and has been reported to restore NIS expression 
in FTC-133 (27), but not in NPA, FRO or ARO cells. Additionaly 
RA does not inhibit growth of FRO and ARO cells that have lost 
RARβ (28), which occurs as a result of promoter hypermethyl-
ation in numerous thyroid cancer cell lines (29). Thus, PPs that 
inhibit RARβ hypermethylation, when administered in combi-
nation with low-dose RA, may be effective in thyroid cancers 
that are refractory to RA therapy. Serum concentrations of PPs 
typically do not exceed 10 μM in humans, a concentration that 
is both antiproliferative and induces redifferentiative in vitro. 
The tissue concentration levels of these compounds can increase 
1-10 fold following dietary supplementation (30). 
  In conclusion these findings suggest that genistein, resvera-
trol and quercetin may be effective for thyroid cancer rediffer-
entiation therapy, including of undifferentiated/anaplastic can-
cers. Further investigations are required to increase the tissue 
concentrations of these polyphenol phytochemicals in thyroid 
cancer patients and to assess their effectiveness in patients with 
dedifferentiated thyroid cancers. 
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This study assessed the ability of polyphenol phytochemicals (PPs) as a redifferentiatiion therapy in thyroid cancer cells. Using F9 
cell differentiation model for the selection of effective PPs, we demonstrated that genistein, resveratrol, quercetin were effective. 
In five kinds of thyroid cancer cell lines, we further demonstrated that the PPs not only decrease the dedifferention markers, but 
also increase the expression of differentiation marker. These findings suggest that the PPs investigated in this study might be 
considered for the redfferentiation therapy of thyroid cancer.